BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval from the National Medical Products Administration (NMPA) to transfer the Marketing Authorization Holder (MAH) for its product Stilamin (somatostatin) in mainland China. The natural peptide hormone, somatostatin, is utilized in the treatment of acute bleeding from esophageal varices, gastrointestinal ulcers, and gastritis, as well as in preventing pancreatic complications post-surgery and regulating secretions from the upper intestine, pancreas, and biliary tract.
In May 2023, Hasten Bio acquired the commercialization rights for Stilamin, originally produced by Merck Serono, for Greater China and Switzerland. The transition of the MAH from Merck to Hasten Bio’s wholly owned subsidiary, Hasten Biopharmaceutic (Switzerland) AG, was completed in December 2023. Further expanding its reach, Hasten Bio successfully transferred the MAH in Taiwan in June 2024.
This series of MAH transfers underscores Hasten Bio’s strategic expansion in the biopharmaceutical sector, highlighting the company’s commitment to broadening access to essential treatments across the region. With the support of the CBC Group, Hasten Bio is well-positioned to enhance its market presence and contribute to the healthcare landscape in China and beyond.- Flcube.com
